M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

NCT03517969 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

73

Enrollment

NIH

Sponsor class

Conditions

Castration-Resistant Prostate Carcinoma
Metastatic Prostate Carcinoma
Stage IV Prostate Cancer AJCC v8

Interventions

DRUG: Berzosertib
DRUG: Carboplatin
DRUG: Docetaxel
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)